Dermatology

FDA Approves Steqeyma for Children With Plaque Psoriasis, Psoriatic Arthritis

June 17th 2025

By Skylar Jeremias

Celltrion's FDA approval of Steqeyma enhances pediatric psoriasis treatment, offering flexible dosing options for children with chronic inflammatory conditions.

Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan

June 17th 2025

By Skylar Jeremias

Article

Alvotech and Dr. Reddy's partner to develop a Keytruda biosimilar, a German court bans Humira biosimilar over patent dispute, and Samsung Bioepis enters a strategic agreement with NIPRO Corporation in Japan.

New Data Support Hulio as an Interchangeable Adalimumab Option

June 16th 2025

By Skylar Jeremias

Article

The new data were collected to fulfill the FDA's requirements to designate adalimumab-fkjp (Hulio) as interchangeable with Humira, enhancing access to affordable biologics for chronic plaque psoriasis treatment.

Biosimilar FYB202 Shows Therapeutic Equivalence to Ustekinumab for Plaque Psoriasis

June 12th 2025

By Cameron Santoro

Article

Switching from reference ustekinumab to biosimilar FYB202 maintained comparable efficacy, safety, and immunogenicity in patients with moderate to severe plaque psoriasis.

European Data Confirm Real-World Benefits of Adalimumab Biosimilars

June 11th 2025

By Skylar Jeremias

Article

New research highlights the efficacy and high patient satisfaction of adalimumab biosimilars in treating inflammatory diseases.

Eye on Pharma: Interchangeability Labels and Expanded Biosimilar Partnerships

May 29th 2025

By Skylar Jeremias

Article

The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple sclerosis, while 2 other companies expand their biosimilar partnership to include more products.

British Columbia’s Biosimilar Policy Shows No Impact on Hospital Visits

May 28th 2025

By Skylar Jeremias

Article

Despite a dramatic shift toward biosimilar use following British Columbia’s policy, researchers found no rise in hospital visits or complications, underscoring the real-world reliability of etanercept biosimilars in managing inflammatory arthritis.

Automatic Biosimilar Substitution and Patient Education Advocated by Elena Wolff-Holz, MD

May 26th 2025

By Cameron Santoro

Video

Elena Wolff-Holz, MD, discussed the rationale and safety surrounding the automatic substitution of biosimilars at the pharmacy level, as well as common misconceptions about these medications.

Differences in Psoriasis Treatment: Ustekinumab Dose Escalation vs Adalimumab, Etanercept Discontinuation

May 22nd 2025

By Cameron Santoro

Article

Dose escalations were more frequent with ustekinumab in patients with psoriasis compared with adalimumab and etanercept, highlighting varied outcomes for dose optimization in psoriasis management.

Paving the Way for Equitable Biosimilar Access in Australian Dermatology Clinics

May 13th 2025

By Skylar Jeremias

Article

Australia’s growing reliance on high-cost biologics for inflammatory skin diseases has placed significant pressure on its health system—but a new report suggests biosimilars could offer financial relief, provided uptake barriers are addressed through policy reform and education.